Amarin Corporation PLC at JPMorgan Healthcare Conference (Virtual) Transcript
Hey, good morning, everyone. My name is Jess Fye. I'm one of the senior biotech analysts at JPMorgan. We're continuing the 40th Healthcare Conference today with Amarin. I'm joined by the company's CEO, Karim Mikhail. He's going to give a presentation, and then we're going to do some Q&A afterwards. (Operator Instructions) So with that, let me pass it over to Karim.
Thank you, Jessica, and good morning, everyone. In today's presentation, I may make forward-looking statements for a complete of risk factors associated with investing in Amarin, please refer to our SEC filing.
So at Amarin, we have a bold vision to stop heart disease from being a leading cause of test. And in today's world, and I'm today on Slide #4, it is very bold as a vision because people don't realize it, but cardiovascular disease is really maybe the most enormous and worsening public health problem we have today.
And whether
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
